Mitsikostas DD, Papadopoulos D. Comparing benefit-risk profiles of oral DMTs for relapsing MS: a likelihood of Help vs. Harm (LHH) Analysis. AAN 2018, P4.388.
MS: COVID-19, uitgesteld doseren natalizumab en nieuwe middelen
dec 2020 | Multipele Sclerose